Actively Recruiting

Phase 1
Phase 2
Age: 12Months +
All Genders
Healthy Volunteers
NCT05478720

DON in Pediatric Cerebral Malaria

Led by Douglas Postels, MD, MS · Updated on 2025-07-31

152

Participants Needed

2

Research Sites

171 weeks

Total Duration

On this page

Sponsors

D

Douglas Postels, MD, MS

Lead Sponsor

N

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are: * Determine the pharmacokinetic (PK) profile of a single dose of DON in children with CM * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with improved intracerebral blood flow dynamics on transcranial doppler (TCD) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with a reduction in brain volume score on magnetic resonance imaging (MRI) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with cerebral malaria is associated with changes in electroencephalogram (EEG) pattern * Exploratory: Explore the metabolic mechanisms of action of adjunctive DON in children with CM Healthy adult participants will receive: * anti-emetic ondansetron * one dose of DON Adults with uncomplicated malaria will receive: * anti-emetic ondansetron * one dose of DON * artemisinin-combination therapies per Malawi Ministry of Health guidelines Pediatric participants will receive: * one dose of DON * anti-emetic ondansetron and per Malawi Ministry of Health guidelines: * enteral lumefantrine-artemether therapy, and * artesunate therapy

CONDITIONS

Official Title

DON in Pediatric Cerebral Malaria

Who Can Participate

Age: 12Months +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years and older for healthy and uncomplicated malaria groups
  • Children aged 12 months to 14 years with cerebral malaria
  • Signed informed consent obtained from participant or guardian
  • For healthy adults: temperature ≤ 37.5 °C, BMI 18.5-25 kg/m2, normal creatinine levels, hemoglobin ≥ 7 g/dL or hematocrit ≥ 20%, negative malaria blood smear
  • For adults with uncomplicated malaria: temperature ≥ 38 °C or recent fever, positive malaria blood smear, hemoglobin ≥ 7 g/dL or hematocrit ≥ 20%, BMI 18.5-25 kg/m2, normal creatinine, Glasgow coma score of 15, respiratory rate ≤ 20 breaths/min, oxygen saturation ≥ 90% on room air
  • For children with cerebral malaria: temperature ≥ 38 °C or recent fever, positive malaria blood smear, Blantyre coma score ≤ 2, no other cause for coma, hematocrit ≥ 18%, normal creatinine, AST < 280 IU/L, ALT < 195 IU/L, negative pregnancy test if applicable
Not Eligible

You will not qualify if you...

  • Pregnancy or lactation; persons of childbearing potential must have negative pregnancy tests
  • Planning pregnancy or attempting to become pregnant
  • Currently taking highly active antiretroviral therapy (HAART)
  • Currently taking anti-tuberculosis medications
  • Allergy to ondansetron
  • For children with cerebral malaria: cloudy cerebrospinal fluid indicating possible bacterial infection
  • Severe malnutrition defined as ≥ 2 standard deviations below mean weight for height or MUAC ≤ 12.5 cm
  • Allergy to ondansetron or ceftriaxone
  • Coma lasting longer than 72 hours
  • Use of CYP3A4 inhibitors within 7 days before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Ndirande Research Clinic

Blantyre, Malawi

Completed

2

Queen Elizabeth Central Hospital

Blantyre, Malawi

Actively Recruiting

Loading map...

Research Team

Y

Yamikani Chimalizeni, MD

CONTACT

A

Alice Liomba

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

13

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here